Publications by authors named "Helene Losson"

Claim this Profile
H
HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics.
Cristina Florean, Manon Lernoux, Anne Lorant, Helene Losson, Guy Bormans

Haematologica· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Hélène Losson, Sruthi Reddy Gajulapalli, Manon Lernoux, Jin-Young Lee, Aloran Mazumder

Pharmacol Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Manon Lernoux, Michael Schnekenburger, Hélène Losson, Koen Vermeulen, Hyunggu Hahn

Clin Epigenetics· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?
Hélène Losson, Michael Schnekenburger, Mario Dicato, Marc Diederich

Cancers (Basel)· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer.
Hélène Losson, Michael Schnekenburger, Mario Dicato, Marc Diederich

Molecules· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis